ArticleCancer management and research2018
Silencing the expression of copine-III enhances the sensitivity of hepatocellular carcinoma cells to the molecular targeted agent sorafenib.
Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Loss of Copine D Leads to Ras Activation inCells · 2026Article
- Loss of Copine D Leads to Ras Activation inbioRxiv : the preprint server for biology · 2026Article
- CPNE3 promotes colorectal cancer progression by regulating KIF4-mediated autophagy.Journal of gastrointestinal oncology · 2026Article
- Integrated analysis of the oncogenic value of CPNE3 in non-small cell lung cancer.Discover oncology · 2025Article
- Targeting MET Signalling Activated by CPNE3-RACK1 Interaction Through VWFA Domain to Suppress Lung Cancer Progression.Journal of cellular and molecular medicine · 2025Article
- Article
- Copine C plays a role in adhesion and streaming inCell adhesion & migration · 2024Article
- YAP1-CPNE3 positive feedback pathway promotes gastric cancer cell progression.Cellular and molecular life sciences : CMLS · 2024Article
- [High expression of CPNE3 correlates with poor long-term prognosis of gastric cancer by inhibiting cell apoptosisNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024Article
- Copine 3 "CPNE3" is a novel regulator for insulin secretion and glucose uptake in pancreatic β-cells.Scientific reports · 2021Article
- The CPNE Family and Their Role in Cancers.Frontiers in genetics · 2021Review
- Systemic Treatment Options in Hepatocellular Carcinoma.Liver cancer · 2019Review
- The Roles Of Angiogenesis And Cancer Stem Cells In Sorafenib Drug Resistance In Hepatocellular Carcinoma.OncoTargets and therapy · 2019Article
- MicroRNA-940 restricts the expression of metastasis-associated gene MACC1 and enhances the antitumor effect of Anlotinib on colorectal cancer.OncoTargets and therapy · 2019Article
- MicroRNA-645 targets urokinase plasminogen activator and decreases the invasive growth of MDA-MB-231 triple-negative breast cancer cells.OncoTargets and therapy · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe application of the oral targeted therapeutic agent sorafenib provides new hope for patients suffering from advanced stages of hepatocellular carcinoma (HCC), but the prognosis of such patients remains poor due to the rapid development of the multidrug resistance process in cancer pathogenesis. The present work evaluated whether copine-III, a novel cancer regulator encoded by the MATERIALS AND
methodsThe endogenous expression of copine-III in clinical specimens was examined by quantitative polymerase chain reaction. Copine-III siRNA was transfected into HCC cells to downregulate copine-III expression. The effect of copine-III on sorafenib's antitumor activation was identified by in vitro and in vivo experiments (MTT, Transwell, and flow cytometry as well as a nude mice model).
resultsHigh levels of copine-III in clinical specimens are related to poor prognosis of advanced HCC patients on sorafenib treatment. Infection of Ad-siCPNE3 significantly decreased the endogenous expression of copine-III and enhanced the susceptibility of MHCC97-H cells to sorafenib: the IC
conclusionCopine-III is a novel potential indicator of prognosis for patients who received sorafenib for advanced HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.